Therapeutic approach to giant cell arteritis

Area of Science:

• Rheumatology
• Vascular Medicine
• Immunology

Background:

• Giant cell arteritis (GCA) is a vasculitis impacting medium and large arteries, primarily in individuals over 50.
• It presents with focal arterial inflammation leading to stenosis or occlusion, alongside systemic symptoms like polymyalgia rheumatica and anemia.
• Commonly affected vessels include external carotid arteries, aorta, and major limb arteries.

Purpose of the Study:

• To summarize the key aspects of Giant Cell Arteritis, including its pathology, clinical presentation, and current treatment strategies.
• To highlight the limitations and challenges associated with current therapies, particularly glucocorticoids.
• To briefly touch upon emerging therapeutic targets and patient outcomes.

Main Methods:

• Review of existing literature on Giant Cell Arteritis.
• Analysis of clinical manifestations, diagnostic criteria, and treatment responses.
• Discussion of immunological pathways involved in GCA pathogenesis.

Main Results:

• GCA involves focal inflammation causing arterial narrowing and systemic effects.
• Glucocorticoids are the mainstay treatment, initiated urgently for visual symptoms, but carry significant side effects and unpredictable duration.
• While Th17 pathways are targeted by glucocorticoids, Th1 pathways may contribute to chronic disease; other treatments like methotrexate and TNFα antagonists show limited efficacy, with some response to tocilizumab (IL-6 inhibitor).

Conclusions:

• GCA management requires prompt glucocorticoid initiation, especially with visual compromise.
• Long-term glucocorticoid therapy is often necessary but associated with considerable morbidity.
• Further research is needed to identify more effective and safer treatments for GCA, considering its chronic and relapsing nature.